Marignier R, Hacohen Y, Cobo-Calvo A, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021;20:762–72.

Article  CAS  PubMed  Google Scholar 

Reindl M, Di Pauli F, Rostásy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. 2013;9:455–61.

Article  CAS  PubMed  Google Scholar 

Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140:3128–38.

Article  PubMed  Google Scholar 

Cobo-Calvo A, Ruiz A, Rollot F, et al. Clinical features and risk of relapses in children and adults with MOGAD. Ann Neurol. 2021;89:30–41.

Article  CAS  PubMed  Google Scholar 

•• Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22:268–82. The diagnostic criteria proposed by the International MOGAD Panel are critical for understanding the diagnosis of MOGAD and will be used in the future to optimize the design of treatment trials.

De Mol C, Wong Y, Van Pelt E, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler J. 2020;26:806–14.

Article  Google Scholar 

O’Connell K, Hamilton-Shield A, Woodhall M, et al. Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK. J Neurol Neurosurg Psychiatry. 2020;91:1126–8.

Article  PubMed  Google Scholar 

Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71:324.

Article  PubMed  Google Scholar 

Sundaram S, Nair SS, Jaganmohan D, Unnikrishnan G, Nair M. Relapsing lumbosacral myeloradiculitis: an unusual presentation of MOG antibody disease. Mult Scler. 2020;26:509–11.

Article  PubMed  Google Scholar 

Budhram A, Mirian A, Le C, Hosseini-Moghaddam SM, Sharma M, Nicolle MW. Unilateral cortical FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome. J Neurol. 2019;266:2481–7.

Article  CAS  PubMed  Google Scholar 

Cobo-Calvo A, Ayrignac X, Kerschen P, et al. Cranial nerve involvement in patients with MOG antibody–associated disease. Neurol Neuroimmunol Neuroinflamm. 2019;6:e543.

Demuth S, Guillaume M, Bourre B, et al. Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. J Neuroinflammation. 2022;19:62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoftberger R, Guo Y, Flanagan EP, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020;139:875–92.

Article  PubMed  PubMed Central  Google Scholar 

Whittam DH, Karthikeayan V, Gibbons E, et al. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol. 2020;267:3565–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bruijstens AL, Wendel EM, Lechner C, et al. E.U. paediatric MOG consortium consensus: part 5 - treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020;29:41–53.

Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992;326:581–8.

Article  CAS  PubMed  Google Scholar 

Morrow SA, Fraser JA, Day C, et al. Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial. JAMA Neurol. 2018;75:690–6.

Article  PubMed  PubMed Central  Google Scholar 

Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-positive optic neuritis: clinical characteristics, radiologic clues and outcome. Am J Ophthalmol. 2018;195:8–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13:280.

Rode J, Pique J, Maarouf A, et al. Time to steroids impacts visual outcome of optic neuritis in MOGAD. J Neurol Neurosurg Psychiatry. 2023;94:309–13.

Article  PubMed  Google Scholar 

Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019;6:e572.

Kleiter I, Gahlen A, Borisow N, et al. Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018;5:e504.

Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89:346–51.

Article  PubMed  Google Scholar 

Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89(2):127–37.

Article  PubMed  Google Scholar 

Nosadini M, Eyre M, Giacomini T, et al. Early immunotherapy and longer corticosteroid treatment are associated with lower risk of relapsing disease course in pediatric MOGAD. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200065.

Camera V, Holm-Mercer L, Ali AAH, et al. Frequency of new silent MRI lesions in myelin oligodendrocyte glycoprotein antibody disease and aquaporin-4 antibody neuromyelitis optica spectrum disorder. JAMA Netw Open. 2021;4:e2137833.

Fadda G, Banwell B, Waters P, et al. Silent new brain MRI lesions in children with MOG-antibody associated disease. Ann Neurol. 2021;89:408–13.

Article  CAS  PubMed  Google Scholar 

Lopez-Chiriboga AS, Sechi E, Buciuc M, et al. Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G–associated disorder. JAMA Neurol. 2020;77:1575.

Article  PubMed  PubMed Central  Google Scholar 

Akaishi T, Misu T, Takahashi T, et al. Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders. J Neuroimmunol. 2021;351:577467.

• Satukijchai C, Mariano R, Messina S, et al. Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom. JAMA Netw Open. 2022;5:e2142780. This prospective multicenter cohort study provides valuable information on predicting the course of MOGAD.

Waters P, Fadda G, Woodhall M, et al. Serial anti–myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurol. 2020;77:82.

Article  PubMed  Google Scholar 

Lopez-Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol. 2018;75:1355–63.

Article  PubMed  PubMed Central  Google Scholar 

Carta S, Cobo Calvo Á, Armangué T, et al. Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study. Neurology. 2023;100:e1095–108.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Redenbaugh V, Flanagan EP. Monoclonal antibody therapies beyond complement for NMOSD and MOGAD. Neurotherapeutics. 2022;19(3):808–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Ani A, Chen JJ, Costello F. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges. J Neurol. 2023;270:4132–50.

Article  PubMed  Google Scholar 

Chwalisz BK, Levy M. The treatment of myelin oligodendrocyte glycoprotein antibody disease: a state-of-the-art review. J Neuroophthalmol. 2022;42:292–6.

Article  PubMed  Google Scholar 

Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020;95:e111–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hacohen Y, Wong YY, Lechner C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 2018;75:478–87.

Article  PubMed  PubMed Central  Google Scholar 

•• Chen JJ, Huda S, Hacohen Y, et al. Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody–associated disease. JAMA Neurol. 2022;79:518–25. This study contains the largest multicenter experience with IVIg use for prevention of MOGAD relapses and underscores the promise of IVIg use as a maintenance therapy.

Cobo-Calvo A, Sepúlveda M, Rollot F, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation. 2019;16:134.

Article  PubMed  PubMed Central  Google Scholar 

Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders. JAMA Neurol. 2016;73:1342–1342.

Article  PubMed  Google Scholar 

Brancati S, Gozzo L, Longo L, Vitale DC, Drago F. Rituximab in multiple sclerosis: are we ready for regulatory approval? Front Immunol. 2021;12.

Spagni G, Sun B, Monte G, et al. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2023;94:62–9.

Article  PubMed  Google Scholar 

Nepal G, Kharel S, Coghlan MA, Rayamajhi P, Ojha R. Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): a systematic review and meta-analysis. J Neuroimmunol. 2022;364:577812.

Starvaggi Cucuzza C, Longinetti E, Ruffin N, et al. Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200056.

Bruschi N, Malentacchi M, Malucchi S, et al. Tailoring rituximab according to CD27-positive B-cell versus CD19-positive B-cell monitoring in neuromyelitis optica spectrum disorder and MOG-associated disease: results from a single-center study. Neurol Ther. 2023;12:1375–83.

Article  PubMed  PubMed Central  Google Scholar 

Barreras P, Vasileiou ES, Filippatou AG, et al. Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease. Neurology. 2022;99:e2504–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Durozard P, Rico A, Boutiere C, et al. Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. Ann Neurol. 2020;87:256–66.

Article  CAS  PubMed